Physician profile
Yuly Chalik
NPI 1730191743
$4,672.97
in general payments reported to CMS, 2019-2025
25 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $124 · 2021: $1,474 · 2022: $834 · 2023: $353 · 2024: $716 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,003.83 | 2023-2025 | Gemtesa |
| Axonics, INC. | $892.47 | 2021-2022 | |
| Teleflex LLC | $565.78 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $436.96 | 2019-2024 | Xtandi |
| Urovant Sciences INC | $411.19 | 2021-2022 | |
| Pfizer INC. | $299.67 | 2019-2023 | |
| Antares Pharma, INC. | $231.16 | 2021-2025 | Xyosted |
| Janssen Biotech, INC. | $154.11 | 2019-2025 | Erleada |
| Myovant Sciences INC. | $110.16 | 2021-2022 | |
| Boston Scientific Corporation | $80.91 | 2019-2024 | Rezum Generator |
| Urogen Pharma, INC. | $64.20 | 2023-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $58.24 | 2019-2024 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $53.55 | 2024 | |
| Myriad Genetic Laboratories, INC. | $51.71 | 2022 | |
| Verity Pharmaceuticals INC. | $43.46 | 2022-2023 | Trelstar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $30.55 | 2024 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $27.87 | 2022 | |
| Neotract INC. | $26.10 | 2020 | |
| Amag Pharmaceuticals, INC. | $22.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.33 | 2024 | Opdivo |
| Clarus Therapeutics INC. | $19.65 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $18.75 | 2019 | |
| Laborie Medical Technologies Corp. | $18.69 | 2025 | |
| Dentsply Ih INC. | $14.98 | 2022 | |
| Abbvie INC. | $14.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuly Chalik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.